Holen Sie sich die Stockscreener-App
3.74
3.86%
-0.15
Handel nachbörslich:
3.77
0.03
+0.80%
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
RXRX Stock Rises As Tempus AI Deal Resets Growth Story - StocksToTrade
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - Yahoo Finance
Recursion Pharmaceuticals, Inc. (RXRX) stock price, news, quote and history - Yahoo Finance UK
Recursion Pharmaceuticals (RXRX) Shares Just Moved, So What Is Driving Attention Now? - simplywall.st
Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know - Yahoo Finance
RXRX Extends Tempus Deal As Stock Climbs On Predictable Cash - timothysykes.com
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: High Potential Upside in the Biotech Sector - DirectorsTalk Interviews
RXRX Stock Grinds Higher As Insider Filings Stack Up - timothysykes.com
A data partnership shifts from potential $84 million in two-year fees to $42 million in committed payments over three - Stock Titan
Recursion Pharmaceuticals (NASDAQ: RXRX) Lowers Tempus Annual Fees to $14 Million - Kalkine Media
Recursion Pharmaceuticals, Inc. Grants Tempus Ai, Inc. Non-Exclusive License for Rna Foundation Model - marketscreener.com
Recursion, Tempus Expand AI and RNA Collaboration Agreements - TipRanks
Recursion Resets Tempus Data Pact and Licenses TxFM RNA Model in $12M Deal - TradingView
Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026SEC Filing - TradingView
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound? - Yahoo Finance
Recursion Pharmaceuticals Inc (RXRX) Stock Price, Quote, News & History - Benzinga
RXRX Stock Holds Support As Insider Form 4s Hit Tape - StocksToTrade
RXRX Stock Steadies As Insider Activity Draws Trader Focus - timothysykes.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Options ChainYahoo Finance - Yahoo! Finance Canada
RXRX Stock Holds Steady As Insider Form 4 Filings Stack Up - timothysykes.com
Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Recursion Pharmaceuticals (RXRX): Can Its AI Platform Translate Into Clinical Wins? - RTTNews
Recursion Pharmaceuticals (RXRX) CFO’s 5,396-share move wasn’t a sale - Stock Titan
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know - finance.yahoo.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Recent Conference Updates and Partnerships - Moomoo
Recursion Pharma CEO Najat Khan sells $78,822 in stock By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals (RXRX) CEO and President Najat Khan Sells 22,408 Shares - GuruFocus
Recursion Pharma CEO Najat Khan sells $78,822 in stock - investing.com
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khan Najat - Moomoo
Recursion Pharmaceuticals CEO Najat Khan Sells 22,408 Shares Under 10b5-1 Plan - Kalkine Media
Recursion Pharmaceuticals (NASDAQ:RXRX) Trades Active As Small-Caps Wobble - Kalkine Media
Recursion (NASDAQ: RXRX) CEO sells 22K shares under preset plan - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Recursion Pharmaceuticals Tokenized Stock (Ondo) price today, RXRXon to USD live price, marketcap and chart - CoinMarketCap
Recursion Pharmaceuticals Stock Short Interest Falls to 34.79% - Moomoo
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
2 Beaten-Down Stocks to Avoid Right Now - theglobeandmail.com
AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider - GlobeNewswire Inc.
Penny Stocks To ResearchSeptember 6th - MarketBeat
Penny Stocks To Follow NowSeptember 5th - MarketBeat
RXRX Tightens Spending As AI Drug Platform Gains Traction - timothysykes.com
RXRX Tightens Cash Burn As AI Drug Pipeline Advances - StocksToTrade
RXRX Tightens Costs As AI Drug Pipeline Advances - timothysykes.com
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? - Yahoo Finance
$Recursion Pharmaceuticals (RXRX.US)$ - Moomoo
RXRX Stock Steadies As AI Drug Engine Tightens Spending - StocksToTrade
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - The Globe and Mail
Recursion Pharmaceuticals director Blake Borgeson sells $100,200 in stock By Investing.com - Investing.com Australia
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake - Moomoo
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Pipeline - Quiver Quantitative
Recursion (NASDAQ: RXRX) director eyes $100K stock sale after recent trades - Stock Titan
RXRX Stock Rallies As AI Drug Platform Tightens Cash Burn - StocksToTrade
Recursion Pharmaceuticals Earnings Call Shows Efficient Progress - TipRanks
Recursion (RXRX) Range: Ends Down by 4.86% at $3.33 in Latest Trading; Range Check: the Current Price Sits Inside the Supplied Technical Range for the Current SessionRisk Parity Rebalance - vinanet.vn
Recursion Pharmaceuticals Stock Climbs 13% As AI Drug Pipeline Progress And Spending Cuts Boost Sentiment - TIKR.com
Recursion, Novavax, Crispr Therapeutics Stocks Slip Premarket After Cancer Therapy RallyRecursion Phar - Benzinga
RXRX Stock Steadies As AI Drug Platform Gains Traction And Cash Burn Tightens - StocksToTrade
Recursion Pharmaceuticals Stock (RXRX) Opinions on Clinical Pipeline and AI Platform Developments - Quiver Quantitative
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):